Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $11
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ:ALLR) with a Buy and raises the price target from $10.25 to $11.
Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ:ALLR) with a Buy and raises the price target from $10.25 to $11.